Edward Sherwood
Last active: 4/3/2019

Profile

The Sherwood research group is studying several aspects of sepsis and the systemic inflammatory response syndrome. A major interest is to define mechanisms of sepsis-induced systemic inflammation and organ injury with emphasis on the roles of natural killer (NK) and T lymphocytes. Current studies are being performed to evaluate the mechanisms of NK and T cell activation and chemotaxis during sepsis with emphasis on the chemokine receptor CXCR3 and its ligands, CXCL9 and CXCL10. The Sherwood group showed that CXCR3 activation is crucial for NK cell trafficking during sepsis and that CXCR3 blockade will decrease inflammation and organ injury in experimental models of sepsis. The underlying goal is to further understand the contribution of CXCR3 activation in the pathogenesis of sepsis and develop clinically relevant interventions to block CXCR3 and improve outcome. In further studies, the Sherwood group is evaluating the immunomodulatory properties of TLR4 agonists and their ability to modify the host response to systemic infection. The group showed that the TLR4 agonists lipopolysaccharide and monophosphoryl lipid A are potent immunomodulators that alter systemic cytokine production and enhance innate resistance to bacterial infections. The improved resistance to infection is caused by neutrophil expansion and enhanced neutrophil functions. The group is working to define the mechanisms by which TLR4 agonists promote the antimicrobial functions of neutrophils and develop TLR4 agonists as agents that can be used clinically to improve the resistance of critically ill patients to infection.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism. Fensterheim BA, Young JD, Luan L, Kleinbard RR, Stothers CL, Patil NK, McAtee-Pereira AG, Guo Y, Trenary I, Hernandez A, Fults JB, Williams DL, Sherwood ER, Bohannon JK (2018) J Immunol 200(11): 3777-3789
    › Primary publication · 29686054 (PubMed) · PMC5964009 (PubMed Central)
  2. The Cytokine Response to Lipopolysaccharide Does Not Predict the Host Response to Infection. Fensterheim BA, Guo Y, Sherwood ER, Bohannon JK (2017) J Immunol 198(8): 3264-3273
    › Primary publication · 28275139 (PubMed) · PMC5380530 (PubMed Central)
  3. WHAT'S NEW IN SHOCK? OCTOBER 2015. Sherwood ER (2015) Shock 44(4): 291-3
    › Primary publication · 26263441 (PubMed)
  4. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ. Guo Y, Luan L, Rabacal W, Bohannon JK, Fensterheim BA, Hernandez A, Sherwood ER (2015) J Immunol 195(5): 2353-64
    › Primary publication · 26216888 (PubMed) · PMC4543906 (PubMed Central)
  5. Immunology. Getting sepsis therapy right. Hotchkiss RS, Sherwood ER (2015) Science 347(6227): 1201-2
    › Primary publication · 25766219 (PubMed) · PMC4398343 (PubMed Central)
  6. Monophosphoryl lipid A inhibits the cytokine response of endothelial cells challenged with LPS. Stark R, Choi H, Koch S, Lamb F, Sherwood E (2015) Innate Immun 21(6): 565-74
    › Primary publication · 25540284 (PubMed) · PMC4480205 (PubMed Central)
  7. Endothelial dysfunction is a potential contributor to multiple organ failure and mortality in aged mice subjected to septic shock: preclinical studies in a murine model of cecal ligation and puncture. Coletta C, Módis K, Oláh G, Brunyánszki A, Herzig DS, Sherwood ER, Ungvári Z, Szabo C (2014) Crit Care 18(5): 511
    › Primary publication · 25223540 (PubMed) · PMC4177582 (PubMed Central)
  8. The role of CXCL10 in the pathogenesis of experimental septic shock. Herzig DS, Luan L, Bohannon JK, Toliver-Kinsky TE, Guo Y, Sherwood ER (2014) Crit Care 18(3): R113
    › Primary publication · 24890566 (PubMed) · PMC4075230 (PubMed Central)
  9. BTLA as a biomarker and mediator of sepsis-induced immunosuppression. Sherwood ER, Hotchkiss RS (2013) Crit Care 17(6): 1022
    › Primary publication · 24321139 (PubMed) · PMC4059397 (PubMed Central)
  10. Lung ventilation strategies and regional lung inflammation. Luan L, Hernandez A, Sherwood ER (2013) Crit Care 17(5): 184
    › Primary publication · 24007679 (PubMed) · PMC4057236 (PubMed Central)
  11. The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants. Bohannon JK, Hernandez A, Enkhbaatar P, Adams WL, Sherwood ER (2013) Shock 40(6): 451-62
    › Primary publication · 23989337 (PubMed) · PMC3919163 (PubMed Central)
  12. What's new in Shock? September 2013. Sherwood E (2013) Shock 40(3): 163-5
    › Primary publication · 23949390 (PubMed)
  13. A two-hit mechanism for sepsis-induced impairment of renal tubule function. Watts BA, George T, Sherwood ER, Good DW (2013) Am J Physiol Renal Physiol 304(7): F863-74
    › Primary publication · 23324175 (PubMed) · PMC3625847 (PubMed Central)
  14. The role of natural killer cells in the pathogenesis of sepsis: the ongoing enigma. Bohannon J, Guo Y, Sherwood ER (2012) Crit Care 16(6): 185
    › Primary publication · 23234545 (PubMed) · PMC3672611 (PubMed Central)
  15. Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis. Herzig DS, Guo Y, Fang G, Toliver-Kinsky TE, Sherwood ER (2012) Crit Care 16(5): R168
    › Primary publication · 22992408 (PubMed) · PMC3682267 (PubMed Central)
  16. STAT1-deficient mice are resistant to cecal ligation and puncture-induced septic shock. Herzig D, Fang G, Toliver-Kinsky TE, Guo Y, Bohannon J, Sherwood ER (2012) Shock 38(4): 395-402
    › Primary publication · 22777121 (PubMed) · PMC3445722 (PubMed Central)
  17. Regulation of lymphocyte trafficking by CXC chemokine receptor 3 during septic shock. Herzig DS, Driver BR, Fang G, Toliver-Kinsky TE, Shute EN, Sherwood ER (2012) Am J Respir Crit Care Med 185(3): 291-300
    › Primary publication · 22135342 (PubMed) · PMC3297107 (PubMed Central)
  18. Basolateral LPS inhibits NHE3 and HCOFormula absorption through TLR4/MyD88-dependent ERK activation in medullary thick ascending limb. Watts BA, George T, Sherwood ER, Good DW (2011) Am J Physiol Cell Physiol 301(6): C1296-306
    › Primary publication · 21881005 (PubMed) · PMC3233797 (PubMed Central)
  19. The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER (2011) Infect Immun 79(9): 3576-87
    › Primary publication · 21646453 (PubMed) · PMC3165493 (PubMed Central)
  20. Dendritic cell modification of neutrophil responses to infection after burn injury. Bohannon J, Cui W, Sherwood E, Toliver-Kinsky T (2010) J Immunol 185(5): 2847-53
    › Primary publication · 20679533 (PubMed) · PMC3100157 (PubMed Central)
  21. The role of interferon-γ in the pathogenesis of acute intra-abdominal sepsis. Romero CR, Herzig DS, Etogo A, Nunez J, Mahmoudizad R, Fang G, Murphey ED, Toliver-Kinsky T, Sherwood ER (2010) J Leukoc Biol 88(4): 725-35
    › Primary publication · 20628064 (PubMed) · PMC2974432 (PubMed Central)
  22. Fms-like tyrosine kinase-3 ligand alters antigen-specific responses to infections after severe burn injury. Bohannon J, Fang G, Cui W, Sherwood E, Toliver-Kinsky T (2009) Shock 32(4): 435-41
    › Primary publication · 19752689 (PubMed) · PMC3100155 (PubMed Central)
  23. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. Talon MD, Woodson LC, Sherwood ER, Aarsland A, McRae L, Benham T (2009) J Burn Care Res 30(4): 599-605
    › Primary publication · 19506498 (PubMed)
  24. Pretreatment with the Gram-positive bacterial cell wall molecule peptidoglycan improves bacterial clearance and decreases inflammation and mortality in mice challenged with Staphylococcus aureus. Murphey ED, Fang G, Sherwood ER (2008) Crit Care Med 36(11): 3067-73
    › Primary publication · 18824898 (PubMed) · PMC2610268 (PubMed Central)
  25. Pretreatment with the Gram-positive bacterial cell wall molecule peptidoglycan improves bacterial clearance and decreases inflammation and mortality in mice challenged with Pseudomonas aeruginosa. Murphey ED, Sherwood ER (2008) Microbes Infect 10(12-13): 1244-50
    › Primary publication · 18678270 (PubMed) · PMC2603308 (PubMed Central)
  26. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER (2008) J Immunol 180(9): 6334-45
    › Primary publication · 18424757 (PubMed) · PMC3413484 (PubMed Central)
  27. Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhances global immune responses to infection. Bohannon J, Cui W, Cox R, Przkora R, Sherwood E, Toliver-Kinsky T (2008) J Immunol 180(5): 3038-48
    › Primary publication · 18292526 (PubMed)
  28. Endotoxin pretreatment improves bacterial clearance and decreases mortality in mice challenged with Staphylococcus aureus. Murphey ED, Fang G, Sherwood ER (2008) Shock 29(4): 512-8
    › Primary publication · 17724430 (PubMed)
  29. CD4+ T-cell depletion is not associated with alterations in survival, bacterial clearance, and inflammation after cecal ligation and puncture. Enoh VT, Lin SH, Etogo A, Lin CY, Sherwood ER (2008) Shock 29(1): 56-64
    › Primary publication · 17693926 (PubMed)
  30. Mice depleted of alphabeta but not gammadelta T cells are resistant to mortality caused by cecal ligation and puncture. Enoh VT, Lin SH, Lin CY, Toliver-Kinsky T, Murphey ED, Varma TK, Sherwood ER (2007) Shock 27(5): 507-19
    › Primary publication · 17438456 (PubMed)
  31. Improved bacterial clearance and decreased mortality can be induced by LPS tolerance and is not dependent upon IFN-gamma. Murphey ED, Fang G, Varma TK, Sherwood ER (2007) Shock 27(3): 289-95
    › Primary publication · 17304110 (PubMed)
  32. Effect of transforming growth factor-beta neutralization on survival and bacterial clearance in a murine model of Pseudomonas aeruginosa burn wound infection. Huang Z, Pereira C, Toliver-Kinsky T, Murphey ED, Varma TK, Lin CY, Herndon DN, Sherwood ER (2006) J Burn Care Res 27(5): 682-7
    › Primary publication · 16998401 (PubMed)
  33. Bacterial clearance and mortality are not improved by a combination of IL-10 neutralization and IFN-gamma administration in a murine model of post-CLP immunosuppression. Murphey ED, Sherwood ER (2006) Shock 26(4): 417-24
    › Primary publication · 16980891 (PubMed)
  34. Differential effect of imipenem treatment on wild-type and NK cell-deficient CD8 knockout mice during acute intra-abdominal injury. Enoh VT, Fairchild CD, Lin CY, Varma TK, Sherwood ER (2006) Am J Physiol Regul Integr Comp Physiol 290(3): R685-93
    › Primary publication · 16269570 (PubMed)
  35. Endotoxin priming improves clearance of Pseudomonas aeruginosa in wild-type and interleukin-10 knockout mice. Varma TK, Durham M, Murphey ED, Cui W, Huang Z, Lin CY, Toliver-Kinsky T, Sherwood ER (2005) Infect Immun 73(11): 7340-7
    › Primary publication · 16239532 (PubMed) · PMC1273831 (PubMed Central)
  36. Differential effect of imipenem treatment on injury caused by cecal ligation and puncture in wild-type and NK cell-deficient beta(2)-microgloblin knockout mice. Enoh VT, Lin CY, Varma TK, Sherwood ER (2006) Am J Physiol Gastrointest Liver Physiol 290(2): G277-84
    › Primary publication · 16166341 (PubMed)
  37. Cardiovascular dysfunction caused by cecal ligation and puncture is attenuated in CD8 knockout mice treated with anti-asialoGM1. Tao W, Enoh VT, Lin CY, Johnston WE, Li P, Sherwood ER (2005) Am J Physiol Regul Integr Comp Physiol 289(2): R478-R485
    › Primary publication · 15845883 (PubMed)
  38. Glucan phosphate treatment attenuates burn-induced inflammation and improves resistance to Pseudomonas aeruginosa burn wound infection. Lyuksutova OI, Murphey ED, Toliver-Kinsky TE, Lin CY, Cui W, Williams DL, Sherwood ER (2005) Shock 23(3): 224-32
    › Primary publication · 15718919 (PubMed)
  39. The effects of traumatic brain injury on cerebral blood flow and brain tissue nitric oxide levels and cytokine expression. Ahn MJ, Sherwood ER, Prough DS, Lin CY, DeWitt DS (2004) J Neurotrauma 21(10): 1431-42
    › Primary publication · 15672633 (PubMed)
  40. Enhancement of dendritic cell production by fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection. Toliver-Kinsky TE, Cui W, Murphey ED, Lin C, Sherwood ER (2005) J Immunol 174(1): 404-10
    › Primary publication · 15611264 (PubMed)
  41. Gamma interferon does not enhance clearance of Pseudomonas aeruginosa but does amplify a proinflammatory response in a murine model of postseptic immunosuppression. Murphey ED, Herndon DN, Sherwood ER (2004) Infect Immun 72(12): 6892-901
    › Primary publication · 15557610 (PubMed) · PMC529160 (PubMed Central)
  42. Mice depleted of CD8+ T and NK cells are resistant to injury caused by cecal ligation and puncture. Sherwood ER, Enoh VT, Murphey ED, Lin CY (2004) Lab Invest 84(12): 1655-65
    › Primary publication · 15448711 (PubMed)
  43. Mechanisms of the inflammatory response. Sherwood ER, Toliver-Kinsky T (2004) Best Pract Res Clin Anaesthesiol 18(3): 385-405
    › Primary publication · 15212335 (PubMed)
  44. Selective activation of protein kinase C delta in human neutrophils following ischemia reperfusion of skeletal muscle. Huda R, Vergara LA, Solanki DR, Sherwood ER, Mathru M (2004) Shock 21(6): 500-4
    › Primary publication · 15167677 (PubMed)
  45. Diminished bacterial clearance is associated with decreased IL-12 and interferon-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, Sherwood ER (2004) Shock 21(5): 415-25
    › Primary publication · 15087817 (PubMed)
  46. Hemodynamic and cardiac contractile function during sepsis caused by cecal ligation and puncture in mice. Tao W, Deyo DJ, Traber DL, Johnston WE, Sherwood ER (2004) Shock 21(1): 31-7
    › Primary publication · 14676681 (PubMed)
  47. Effects of aging on mortality, hypothermia, and cytokine induction in mice with endotoxemia or sepsis. Saito H, Sherwood ER, Varma TK, Evers BM (2003) Mech Ageing Dev 124(10-12): 1047-58
    › Primary publication · 14659593 (PubMed)
  48. Beta2-microglobulin knockout mice treated with anti-asialoGM1 exhibit improved hemodynamics and cardiac contractile function during acute intra-abdominal sepsis. Tao W, Sherwood ER (2004) Am J Physiol Regul Integr Comp Physiol 286(3): R569-75
    › Primary publication · 14630624 (PubMed)
  49. Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice. Toliver-Kinsky TE, Lin CY, Herndon DN, Sherwood ER (2003) Infect Immun 71(6): 3058-67
    › Primary publication · 12761083 (PubMed) · PMC155733 (PubMed Central)
  50. Beta 2 microglobulin knockout mice are resistant to lethal intraabdominal sepsis. Sherwood ER, Lin CY, Tao W, Hartmann CA, Dujon JE, French AJ, Varma TK (2003) Am J Respir Crit Care Med 167(12): 1641-9
    › Primary publication · 12626348 (PubMed)
  51. Interferon-gamma production is suppressed in thermally injured mice: decreased production of regulatory cytokines and corresponding receptors. Toliver-Kinsky TE, Varma TK, Lin CY, Herndon DN, Sherwood ER (2002) Shock 18(4): 322-30
    › Primary publication · 12392275 (PubMed)
  52. Endotoxin-induced gamma interferon production: contributing cell types and key regulatory factors. Varma TK, Lin CY, Toliver-Kinsky TE, Sherwood ER (2002) Clin Diagn Lab Immunol 9(3): 530-43
    › Primary publication · 11986256 (PubMed) · PMC119981 (PubMed Central)
  53. Glucan phosphate potentiates endotoxin-induced interferon-gamma expression in immunocompetent mice, but attenuates induction of endotoxin tolerance. Sherwood ER, Varma TK, Fram RY, Lin CY, Koutrouvelis AP, Toliver-Kinsky TE (2001) Clin Sci (Lond) 101(6): 541-50
    › Primary publication · 11724637 (PubMed)
  54. Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxin-tolerant mice. Varma TK, Toliver-Kinsky TE, Lin CY, Koutrouvelis AP, Nichols JE, Sherwood ER (2001) Infect Immun 69(9): 5249-63
    › Primary publication · 11500393 (PubMed) · PMC98633 (PubMed Central)
  55. Interleukin-8, neuroinflammation, and secondary brain injury. Sherwood ER, Prough DS (2000) Crit Care Med 28(4): 1221-3
    › Primary publication · 10809311 (PubMed)
  56. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C (1998) Br J Cancer 77(6): 855-61
    › Primary publication · 9528825 (PubMed) · PMC2150082 (PubMed Central)
  57. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, Lee C (1995) World J Urol 13(5): 290-6
    › Primary publication · 8581000 (PubMed)
  58. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. Theyer G, Schirmböck M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G (1993) J Urol 150(5 Pt 1): 1544-7
    › Primary publication · 8105110 (PubMed)
  59. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. Fong CJ, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C, Kozlowski JM (1993) J Urol 149(5): 1190-4
    › Primary publication · 7683344 (PubMed)
  60. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Kleinerman DI, Troncoso P, Lin SH, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh JT (1995) Cancer Res 55(6): 1215-20
    › Primary publication · 7533659 (PubMed)
  61. Modification of diverse experimental immunosuppressive states by glucan. Di Luzio NR, Williams DL, Sherwood ER, Browder IW (1985) Surv Immunol Res 4(2): 160-7
    › Primary publication · 3898275 (PubMed)
  62. Therapeutic efficacy of glucan in a murine model of hepatic metastatic disease. Williams DL, Sherwood ER, McNamee RB, Jones EL, Di Luzio NR (1985) Hepatology 5(2): 198-206
    › Primary publication · 3884476 (PubMed)
  63. Glucan stimulates production of antitumor cytolytic/cytostatic factor(s) by macrophages. Sherwood ER, Williams DL, Di Luzio NR (1986) J Biol Response Mod 5(6): 504-26
    › Primary publication · 3794756 (PubMed)
  64. Comparison of the in vitro cytolytic effect of hepatic, splenic and peritoneal macrophages from glucan-treated mice on sarcoma M5076. Sherwood ER, Williams DL, Di Luzio NR (1986) Methods Find Exp Clin Pharmacol 8(3): 157-61
    › Primary publication · 3713379 (PubMed)
  65. Enhancement of interleukin-1 and interleukin-2 production by soluble glucan. Sherwood ER, Williams DL, McNamee RB, Jones EL, Browder IW, Di Luzio NR (1987) Int J Immunopharmacol 9(3): 261-7
    › Primary publication · 3497113 (PubMed)
  66. In vitro tumoricidal activity of resting and glucan-activated Kupffer cells. Sherwood ER, Williams DL, McNamee RB, Jones EL, Browder IW, Di Luzio NR (1987) J Leukoc Biol 42(1): 69-75
    › Primary publication · 3474334 (PubMed)
  67. Chemoimmunotherapy of experimental hepatic metastases. Williams DL, Sherwood ER, McNamee RB, Jones EL, Browder IW, Di Luzio NR (1987) Hepatology 7(6): 1296-304
    › Primary publication · 3315933 (PubMed)
  68. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases. Sherwood ER, Williams DL, McNamee RB, Jones EL, Browder IW, Di Luzio NR (1988) J Biol Response Mod 7(2): 185-98
    › Primary publication · 3283299 (PubMed)
  69. Effect of glucan on neutrophil dynamics and immune function in Escherichia coli peritonitis. Williams DL, Sherwood ER, Browder IW, McNamee RB, Jones EL, Rakinic J, Di Luzio NR (1988) J Surg Res 44(1): 54-61
    › Primary publication · 3275833 (PubMed)
  70. Pre-clinical safety evaluation of soluble glucan. Williams DL, Sherwood ER, Browder IW, McNamee RB, Jones EL, Di Luzio NR (1988) Int J Immunopharmacol 10(4): 405-14
    › Primary publication · 3262594 (PubMed)
  71. The role of complement in glucan-induced protection against septic shock. Williams DL, Sherwood ER, Browder IW, McNamee RB, Jones EL, Di Luzio NR (1988) Circ Shock 25(1): 53-60
    › Primary publication · 3042187 (PubMed)
  72. Profile matching and profile subtraction: application of computer-based image analysis system for two-dimensional electrophoresis gels. Lee C, Sherwood ER, Sensibar JA, Berg LA, Chen YC, Tseng CC (1989) Biotechniques 7(4): 374-8
    › Primary publication · 2629850 (PubMed)
  73. Two-dimensional protein profiles of cultured stromal and epithelial cells from hyperplastic human prostate. Sherwood ER, Berg LA, McEwan RN, Pasciak RM, Kozlowski JM, Lee C (1989) J Cell Biochem 40(2): 201-14
    › Primary publication · 2475513 (PubMed)
  74. Stimulation of stromal cell growth by normal rat urothelial cell-derived epidermal growth factor. Noguchi S, Yura Y, Sherwood ER, Kakinuma H, Kashihara N, Oyasu R (1990) Lab Invest 62(5): 538-44
    › Primary publication · 2342329 (PubMed)
  75. Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. Sherwood ER, Pitt Ford TR, Lee C, Kozlowski JM (1990) J Biol Response Mod 9(1): 44-52
    › Primary publication · 2319260 (PubMed)
  76. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. Kim JH, Sherwood ER, Sutkowski DM, Lee C, Kozlowski JM (1991) J Urol 146(1): 171-6
    › Primary publication · 2056586 (PubMed)
  77. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM (1991) Cancer Res 51(11): 2780-5
    › Primary publication · 2032218 (PubMed)
  78. Reconstituted basement membrane promotes morphological and functional differentiation of primary human prostatic epithelial cells. Fong CJ, Sherwood ER, Sutkowski DM, Abu-Jawdeh GM, Yokoo H, Bauer KD, Kozlowski JM, Lee C (1991) Prostate 19(3): 221-35
    › Primary publication · 1719510 (PubMed)
  79. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate. Sherwood ER, Theyer G, Steiner G, Berg LA, Kozlowski JM, Lee C (1991) Prostate 18(4): 303-14
    › Primary publication · 1711687 (PubMed)
  80. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C (1990) J Urol 143(1): 167-71
    › Primary publication · 1688457 (PubMed)
  81. Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. Chang SY, Yu DS, Sherwood ER, Kozlowski JM, Lee C (1992) J Urol 147(4): 1147-50
    › Primary publication · 1552613 (PubMed)
  82. Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture. Sutkowski DM, Fong CJ, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, Lee C (1992) Prostate 21(2): 133-43
    › Primary publication · 1409120 (PubMed)
  83. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Fong CJ, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM (1992) Cancer Res 52(21): 5887-92
    › Primary publication · 1394216 (PubMed)
  84. Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions. Fong CJ, Sherwood ER, Braun EJ, Berg LA, Lee C, Kozlowski JM (1992) Prostate 21(2): 121-31
    › Primary publication · 1384014 (PubMed)
  85. Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Sherwood ER, Fong CJ, Lee C, Kozlowski JM (1992) Endocrinology 130(5): 2955-63
    › Primary publication · 1374018 (PubMed)